| Species |
Human |
| Protein Construction |
| Avi |
His |
CCL5 (Ser24-Ser91)
Accession # P13501 |
| N-term |
|
C-term |
|
| Conjugate |
Biotin |
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized CCL5[Biotin], His & Avi, Human at 1μg/ml (100μl/Well) on streptavidin (5μg/ml) precoated plate can bind AntiCCL5 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
E.coli |
| Theoretical Molecular Weight |
10.89 kDa |
| Apparent Molecular Weight |
The protein has a predicted MW of 10.89 kDa same as Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in 4mM HCI. |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in 4mM HCI. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
The CCR5 and the CCL5 ligand have been detected in some hematological malignancies, lymphomas, and a great number of solid tumors, but extensive studies on the role of the CCL5/CCR axis were performed only in a limited number of cancers. |
| Synonyms |
MuRantes; SIS-delta; Scya5; Ccl5; D17S136E; eoCP; RANTES; SCYA5; SISd; TCP228; CCL5 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
